NEW YORK, April 2, 2014 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that one oral presentation and four posters on ITI-007, the Company's lead drug candidate for the treatment of schizophrenia, behavioral disturbances in dementia, bipolar disorder and other neuropsychiatric and neurological disorders, will be featured at the 4th Biennial Schizophrenia International Research Society (SIRS) Conference. The meeting will be held April 5-9, 2014, in Florence, Italy. The presentation and posters will feature data from ITI-007-005, the Company's recently completed Phase 2 clinical trial in patients with an acutely exacerbated episode of schizophrenia, as well as data on the metabolism, unique target profile, and mechanism of action of ITI-007.
Help employers find you! Check out all the jobs and post your resume.
